会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS
    • 二氨基苯并噻唑鎓化合物的合成和/或纯化方法
    • EP2057136B1
    • 2013-05-22
    • EP07733509.9
    • 2007-07-10
    • Wista Laboratories Ltd.
    • WISCHIK, Claude, MichelSTOREY, John, Mervyn, DavidMARSHALL, ColinSINCLAIR, James, PeterBADDELEY, Thomas, Craven
    • C07D279/18
    • A61K31/5415C07D279/18C07D279/20
    • This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto-temporal dementia (FTD); FTD and parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCl); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).
    • 7. 发明公开
    • METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS
    • 二氨基苯并噻唑鎓化合物的合成和/或纯化方法
    • EP2057136A2
    • 2009-05-13
    • EP07733509.9
    • 2007-07-10
    • Wista Laboratories Ltd.
    • WISCHIK, Claude, MichelSTOREY, John, Mervyn, DavidMARSHALL, ColinSINCLAIR, James, PeterBADDELEY, Thomas, Craven
    • C07D279/18
    • A61K31/5415C07D279/18C07D279/20
    • This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto-temporal dementia (FTD); FTD and parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCl); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).
    • 本发明一般涉及化学合成和纯化领域,更具体地涉及某些3,7-二氨基 - 吩噻嗪-5-鎓化合物(本文称为“二氨基吩噻嗪鎓化合物”)的合成和/或纯化方法,包括甲基硫堇鎓氯化物 (MTC)(也称为亚甲蓝)。 本发明还涉及所得(高纯度)化合物,包含它们的组合物(例如片剂,胶囊),以及它们在灭活病原体的方法中的用途,以及医学治疗,预防和诊断等的方法 ,一种tau蛋白病; τ蛋白质聚集的疾病; 阿尔茨海默病(AD); 皮克氏病; 进行性核上性麻痹(PSP); 额颞叶痴呆(FTD); 与17号染色​​体相关的帕金森综合征(FTDP-17); 去抑制 - 痴呆 - 帕金森病 - 肌萎缩综合征(DDPAC); 苍白球 - 黑质变性(PPND); 关岛 - ALS综合征; pallido-nigro-luysian degeneration(PNLD); 皮质基底变性(CBD); 轻度认知障碍(MCI); 皮肤癌; 黑色素瘤; 高铁血红蛋白血症; 病毒感染; 细菌感染; 原虫感染; 寄生虫感染; 疟疾; 内脏利什曼病; 非洲昏睡病; 弓形虫病; 贾第虫病; 南美锥虫病; 丙型肝炎病毒(HCV)感染; 人类免疫缺陷病毒(HIV)感染; 西尼罗河病毒(WNV)感染; 突触核蛋白病; 帕金森病(PD); 路易体痴呆(DLB); 多系统萎缩(MSA); 药物性帕金森综合征; 和纯自主神经衰竭(PAF)。